Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials

Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study

(2017) Kimberley Kavanagh et al.   LANCET INFECTIOUS DISEASES

Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe

(2017) Susanne Hartwig et al.   Infectious Agents and Cancer

Surveillance of effects of HPV vaccination in Belgium

(2016) Marc Arbyn et al.   Cancer Epidemiology

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

(2016) Cosette M Wheeler et al.   LANCET INFECTIOUS DISEASES

Is HPV vaccination in pregnancy safe?

(2016) Ulla Bonde et al.   Human Vaccines & Immunotherapeutics

Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial

(2016) Feng-cai Zhu et al.   Cancer Medicine

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials

(2015) Aimée R Kreimer et al.   LANCET ONCOLOGY

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

(2015) Nelly Mugo et al.   Human Vaccines & Immunotherapeutics

Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: Results from a randomized controlled trial

(2014) Feng-Cai Zhu et al.   INTERNATIONAL JOURNAL OF CANCER

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years

(2014) Fengcai Zhu et al.   Human Vaccines & Immunotherapeutics

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women

(2014) Ryo Konno et al.   Human Vaccines & Immunotherapeutics

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine

(2014) Paulo S Naud et al.   Human Vaccines & Immunotherapeutics

Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years

(2013) Hiroyuki Yoshikawa et al.   CANCER SCIENCE

A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types

(2013) Davit Bzhalava et al.   VIROLOGY

Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young Women

(2012) Papa Salif Sow et al.   JOURNAL OF INFECTIOUS DISEASES

Human Papillomavirus Vaccines – Immune Responses

(2012) Margaret Stanley et al.   VACCINE

Worldwide burden of cervical cancer in 2008

(2011) M. Arbyn et al.   ANNALS OF ONCOLOGY

End-of-study safety, immunogenicity and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

(2011) X Castellsagué et al.   BRITISH JOURNAL OF CANCER

Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine in Girls

(2011) Court Pedersen et al.   JOURNAL OF ADOLESCENT HEALTH

Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women

(2011) Seung Cheol Kim et al.   Journal of Gynecologic Oncology

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Matti Lehtinen et al.   LANCET ONCOLOGY

Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: Randomized study in healthy girls

(2011) Channa E. Schmeink et al.   VACCINE

Why CIN3 and CIN2 should be distinguished on histological reports

(2010) A. Herbert et al.   CYTOPATHOLOGY

Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls

(2010) Doris M. Rivera Medina et al.   JOURNAL OF ADOLESCENT HEALTH

Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Cervical Cancer Vaccine Coadministered With Combined Diphtheria-Tetanus-Acellular Pertussis–inactivated Poliovirus Vaccine to Girls and Young Women

(2010) José Garcia-Sicilia et al.   JOURNAL OF ADOLESCENT HEALTH

Cervical Human Papillomavirus Prevalence in 5 Continents: Meta‐Analysis of 1 Million Women with Normal Cytological Findings

(2010) Laia Bruni et al.   JOURNAL OF INFECTIOUS DISEASES

Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years

(2010) Young-Jae Kim et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women

(2010) Neerja Bhatla et al.   JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH

Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine

(2009) Ali Rowhani-Rahbar et al.   VACCINE

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

(2008) Gordon H Guyatt et al.   BMJ-British Medical Journal

Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects

(2007) S. KANG et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER